Time to Treatment Discontinuation and Cost Effectiveness of Third-Line Therapies in Advanced Colorectal Cancer: Real-World Evidence from the NIH All of Us Research Program - Takeaways - MDSpire

Time to Treatment Discontinuation and Cost Effectiveness of Third-Line Therapies in Advanced Colorectal Cancer: Real-World Evidence from the NIH All of Us Research Program

  • By

  • Patrick J. Kiel

  • Mark W. McGiffin

  • Todd C. Skaar

  • Michael A. Preston

  • March 10, 2026

  • 0 min

Share

  • 1

    Immune checkpoint inhibitors (ICI) offer longer treatment persistence in advanced colorectal cancer but at significantly higher costs than regorafenib or trifluridine/tipiracil.

  • 2

    Time to treatment discontinuation is a pragmatic endpoint reflecting treatment durability in advanced colorectal cancer care.

  • 3

    Real-world cost-effectiveness analyses reveal a conflict between the clinical benefits of immunotherapy and its affordability in later-line colorectal cancer treatment.

  • 4

    The NIH All of Us Research Program provides extensive real-world data to evaluate clinical outcomes and cost-effectiveness of ICI in advanced colorectal cancer.

  • 5

    Incomplete biomarker testing data complicates the assessment of ICI use, highlighting challenges in implementing precision oncology in advanced colorectal cancer.

Original Source(s)

Time to Treatment Discontinuation and Cost Effectiveness of Third-Line Therapies in Advanced Colorectal Cancer: Real-World Evidence from the NIH All of Us Research Program

  • by Patrick J. Kiel, Mark W. McGiffin, Todd C. Skaar, Michael A. Preston

  • March 10, 2026

Related Content

Clinical Characteristics and Epidemiological Patterns of Early-Onset Colorectal Cancer in Young Adults and Middle-Aged Individuals: Insights from SEER 17 and GBD 2021 Data Over the Last 15 Years

Utilizing Behaviorally Targeted Text Messaging to Enhance Colon Cancer Screening Rates: A Randomized Quality Improvement Study

Uncertainty-aware and causal test-time adaptive foundation model for robust colorectal cancer pathology diagnosis